SHAREHOLDER ALERT: WeissLaw LLP Investigates Allergan Plc

NEW YORK, June 25, 2019 /PRNewswire/ -- WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Allergan Plc ("Allergan" or the "Company") (NYSE: AGN) in connection with the proposed acquisition of the Company by AbbVie Inc. (NYSE: ABBV).  Under the terms of the agreement, Allergan shareholders will receive $120.30 in cash and 0.8660 shares of ABBV for each share of AGN share they own, representing consideration of $181.32 based on ABBV's June 25 opening price. 

If you own AGN shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

Visit our website
http://www.weisslawllp.com/allergan-plc/

Or follow us on Twitter @MarketsAlert

WeissLaw is investigating whether Allergan's Board acted to maximize shareholder value prior to entering into the acquisition agreement.  Notably, at least one analyst set a target price of $255.00, or approximately $74 above the per share consideration.

WeissLaw is investigating whether Allergan' Board conducted a fair process in agreeing to the proposed acquisition, whether the proposed acquisition undervalues the Company, and whether all material information related to the proposed acquisition is fully and fairly disclosed. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

SOURCE WeissLaw LLP